News
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter and first nine months of 2021.
In Q3 2021, net sales rose 11% (+10% at constant exchange rates
QIAGEN meldet starke Ergebnisse für das dritte Quartal und die ersten neun Monate 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse für das dritte Quartal und die ersten neun Monate 2021 bekannt.
Der Konzernumsatz stieg im dritten Quartal 2021 um
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Charles River Laboratories Announces Third-Quarter 2021 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2021. For the quarter, revenue was $895.9 million, an increase of 20.5% from $743.3
LivaNova Reports Third Quarter 2021 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2021.
For the third quarter of 2021, worldwide
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE-marking of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly
QIAGEN erweitert das QIAstat-Dx-Testmenü um ein 4-Plex-Atemwegs-Panel zur Differenzierung zwischen Grippe-A- und B-Viren, RSV und SARS-CoV-2
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass der QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 Test für das QIAstat-Dx-System, mit dem innerhalb kurzer
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Premier, Inc. to Host Virtual Investor Day on November 17, 2021
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that the company will host its 2021 Virtual Investor Day on Wednesday, November 17, 2021
Premier, Inc. Reports Fiscal-Year 2022 First-Quarter Results
Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year 2022 first quarter ended September 30, 2021.
"We entered fiscal 2022 with strong momentum and are pleased with
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today
Pipeline Health System, LLC Partners with Premier Inc.
Pipeline Health System, LLC (“Pipeline Health”), an independent network of hospitals across California, Texas and Illinois, has selected Premier Inc. (NASDAQ: PINC), a leading technology-enabled
Acadia Healthcare Reports Third Quarter 2021 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2021.
Third Quarter 2021 Results
The Company reported revenue of
Chemed Reports Third-Quarter 2021 Results - Full-Year 2021 Earnings Guidance Increased
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with
Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026006150/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Premier, Inc. and Resilinc Expand Partnership to Enhance Supply Chain Visibility and Sustainability
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, and Resilinc, the leading supply chain monitoring, mapping and resiliency solution, today announced a new
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities
QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchester’s CityLabs 2.0, a new genomics campus developed with
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.20 per share of Class A common
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 15 presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting from Oct. 24
QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the third quarter and first nine months of 2021 on Wednesday, November 3
Charles River Laboratories Plans to Increase CRADL Capacity in Cambridge
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its Charles River Accelerator and Development Lab (CRADL™) on Binney Street in Cambridge, Massachusetts
Premier Inc. Releases Inaugural Sustainability Report
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today released its inaugural sustainability report detailing companywide initiatives focused on
QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE marking of QIAreach® QuantiFERON®-TB test for tuberculosis (TB) infection, in order to help achieve global